丽珠医药集团股份有限公司投资者关系活动记录表 编号：2023-09 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □其他 活动参与人员 丽珠集团——副总裁、董事会秘书 杨亮 6 场交流会 13 家机构共计 30 人（名单附后） 7 月 5 日 10:00-11:00 7 月 11 日 9:30-10:30 时间 7 月 12 日 10:00-11:00，13:30-14:30 7 月 13 日 10:00-11:00 7 月 14 日 10:00-11:00 地点 本公司办公室 形式 现场调研、线上参会 1、简要介绍公司 2022 年度及 2023 年一季度业绩情况 公司 2022 年实现营业收入 126.3 亿元，同比增长 4.69%；归母净利润为 19.09 亿元，同比增长 7.53%；扣非 归母净利润实现 18.8 亿元，同比增长 15.57%；其中，化 学制剂实现销售收入 70 亿元，同比增长 0.02%；原料药 及中间体业务板块实现收入 31.38 亿元，同比增长 7.89%； 交流内容及具体问答 中药制剂领域实现收入 12.54 ...

Financial Performance - In 2022, the company achieved a revenue of CNY 12.63 billion, a year-on-year increase of 4.69% [1] - The net profit attributable to shareholders was CNY 1.909 billion, up 7.53% year-on-year [1] - In Q1 2023, the company reported a revenue of CNY 3.413 billion, a decrease of 1.90% year-on-year [1] - The net profit attributable to shareholders for Q1 2023 was CNY 582 million, an increase of 5.17% year-on-year [1] Revenue Breakdown by Segment - Chemical preparations generated revenue of CNY 7 billion, a slight increase of 0.02% year-on-year [1] - Raw materials and intermediates achieved revenue of CNY 3.138 billion, a year-on-year increase of 7.89% [1] - Traditional Chinese medicine preparations reported revenue of CNY 1.254 billion, up 17.07% year-on-year [1] - Diagnostic reagents and equipment generated revenue of CNY 724 million, remaining stable [1] - The newly added biopharmaceutical segment achieved revenue of CNY 408 million, a significant increase of 80.94% year-on-year [1] Market Challenges and Outlook - Prescription drug sales faced limitations in Q1 2023, particularly in chemical drugs, which saw a year-on-year decline of 20.95% [2] - The decline was attributed to the impact of inventory buildup during the Spring Festival and the slow recovery of hospital terminals [2] - The company remains optimistic about the sales outlook for 2023, expecting recovery in prescription drug sales from March onwards [2] Product Development and Innovation - The company is advancing the clinical trials for semaglutide, with plans to complete enrollment in 2023 and aim for approval in 2025 [3] - New indications for existing products, such as the injection of esomeprazole sodium, have been approved, expanding market applications [4] - The company is focusing on the development of traditional Chinese medicine products, with plans to enhance R&D capabilities in this area [5] Strategic Initiatives - The establishment of a modernized Chinese medicine technology company aims to innovate and develop new products in the traditional medicine sector [5] - The company is also expanding into the pet medication market, with two products already approved and more in development [6] - Continuous efforts are being made to promote new products and adapt to market changes, ensuring stable growth in revenue [5]

Financial Performance - In 2022, the company achieved a revenue of CNY 12.63 billion, a year-on-year increase of 4.69% [1] - The net profit attributable to shareholders was CNY 1.909 billion, up 7.53% year-on-year [1] - In Q1 2023, the company reported a revenue of CNY 34.13 billion, a decrease of 1.90% year-on-year, with a net profit of CNY 5.82 billion, an increase of 5.17% [2] - The revenue from chemical preparations in Q1 2023 was CNY 16.24 billion, down 20.95% year-on-year [2] Business Segments - Chemical preparations generated revenue of CNY 70 billion in 2022, a slight increase of 0.02% [1] - The raw materials and intermediates segment achieved revenue of CNY 9.96 billion, a growth of 10.64% [2] - The traditional Chinese medicine segment saw revenue of CNY 12.54 billion, up 17.07% [1] - The newly added biopharmaceutical segment generated CNY 4.08 billion, a significant increase of 80.94% [2] R&D and Innovation - The company has maintained a compound annual growth rate of over 15% in net profit for the past decade [2] - R&D investment accounts for over 10% of revenue, focusing on innovative and complex formulations [2] - The company plans to launch an average of 3-5 key formulation products annually [3] Shareholder Returns and ESG - The company has maintained a dividend yield between 3.1% and 4.9% over the past five years, with cumulative dividends of approximately CNY 7.5 billion over the last decade [3] - The company has received an AA rating in MSCI-ESG, placing it among the top 10% of global peers [3] Market Outlook and Strategies - The company is actively expanding its product pipeline through licensing, partnerships, and strategic collaborations [3] - Plans to enhance market presence in the pet medicine sector, with two products already approved and more in development [6] - The company is also focusing on the development of vaccines beyond COVID-19, with ongoing research into multi-valent vaccines [6] Investor Relations Activities - The company engaged with 86 institutions during a recent investor relations event, including major securities firms [1] - The company is committed to maintaining transparent communication with investors and has implemented share buyback programs to enhance shareholder value [5]

Group 1: Financial Performance and Growth - The company reported a revenue growth slowdown in Q1 2023, but management remains confident about the overall annual performance, expecting recovery as hospital operations normalize [3][4]. - The company’s R&D investment was approximately RMB 1.5 billion in 2021 and is expected to remain stable at around RMB 1.5 billion in 2022, with a focus on innovative drugs and complex formulations [9][10]. - The company plans to repurchase shares with a total amount not less than RMB 400 million and not exceeding RMB 800 million, with a repurchase price capped at RMB 40.00 per share [2]. Group 2: Product Development and Pipeline - The company has several products, including Apalutamide and Trastuzumab, that have received new indications and are expected to contribute positively to sales [4][5]. - The company is advancing multiple projects in its pipeline, including the submission of Triptorelin microspheres to the CDE, with expectations for approval in 2023 [7][8]. - The company is focusing on high-value innovative drugs in core areas such as gastrointestinal, mental health, reproductive assistance, and oncology [2][4]. Group 3: Market Strategy and Challenges - The company is adapting to centralized procurement policies by optimizing production costs and reducing marketing expenses [2][3]. - The management emphasizes the importance of maintaining investor confidence through consistent cash dividends and share buybacks [3][8]. - The company is actively enhancing its market presence through digital marketing and expanding its distribution channels [5][6]. Group 4: Regulatory and Compliance - The company adheres strictly to regulations regarding share repurchases and has no intention of manipulating stock prices [2][9]. - The company is committed to transparency and will disclose any significant developments in its product approvals and market strategies [10].

Financial Performance - In 2022, Livzon Pharmaceutical Group achieved a revenue of RMB 12,629.58 million, representing a year-on-year growth of 4.69%[8] - The net profit attributable to shareholders for 2022 was RMB 1,909.39 million, an increase of 7.53% compared to the previous year[8] - Excluding non-recurring gains and losses, the net profit attributable to shareholders from core operations was RMB 1,880.46 million, reflecting a growth of 15.57% year-on-year[8] - The company reported a total revenue of RMB 12,629.58 million for the year, representing a 4.69% increase compared to the previous year[16] - The net profit attributable to shareholders was RMB 1,909.39 million, reflecting a growth of 7.53% year-on-year[16] - The company achieved a 15.57% increase in cash flow from operating activities, amounting to RMB 2,772.67 million[16] - The basic earnings per share for 2022 was RMB 2.04, a 7.37% increase from RMB 1.90 in 2021[42] - The total amount of public welfare donations made by the company during the reporting period was approximately RMB 9.98 million[12] Business Development and Strategy - Livzon is focusing on innovative drug development in areas such as digestive, mental health, reproductive assistance, and oncology, with a differentiated product pipeline covering the entire R&D cycle[11] - The company aims to strengthen its competitive advantage through digital transformation and improved operational management[7] - Livzon is actively pursuing business development opportunities, including potential mergers and acquisitions to enhance its product portfolio and market presence[31] - The company has expanded its market channels and established an internet digital marketing platform to increase product penetration in the OTC retail market[12] - The company is committed to enhancing its R&D pipeline, particularly in high-barrier complex formulations and innovative drugs, to meet evolving market demands[49] - The company is focusing on enhancing its product competitiveness through digital transformation and improving operational efficiency[57] Research and Development - Livzon has established a Clinical Research Management Center to optimize the management structure of its medical, clinical operations, and registration teams[11] - The company completed the Phase III clinical trial for the Semaglutide injection and submitted supplementary materials for the prostate cancer indication of Triptorelin microspheres[12] - The company has 86 ongoing R&D projects as of the end of 2022, with 1 project in the clinical evaluation stage[106] - The company has made significant progress in the research and development of complex formulations and new drugs in oncology, reproductive health, and autoimmune diseases[61] - The company is focusing on the development of new traditional Chinese medicine projects, with eight new drug research projects currently underway[72] Market Expansion - Livzon's market expansion efforts have led to a 20% increase in user data, with a growing customer base in both domestic and international markets[31] - The company is actively expanding its international business, particularly in markets such as Pakistan, Indonesia, and Uzbekistan[60] - The company has successfully registered 5 chemical preparation products in overseas markets and submitted 6 new registrations as of December 31, 2022[63] - The company is advancing the conditional listing application for its recombinant COVID-19 vaccine, which has been included in the national immunization program and is now used in over 20 provinces[64] Corporate Governance and Social Responsibility - The board proposed a cash dividend of RMB 16.00 per 10 shares for the 2022 fiscal year, pending approval at the annual general meeting[10] - The company is committed to social responsibility by providing precise assistance to chronic and rare disease patients, contributing to health initiatives in rural areas[15] - The company has established a foreign exchange risk management system to mitigate exposure from non-RMB transactions[147] Financial Position and Assets - Total assets as of December 31, 2022, reached RMB 24,864.83 million, an increase of 11.14% from RMB 22,371.92 million at the end of 2021[42] - The company reported a total of 935,552,687 shares outstanding as of the last trading day before disclosure[44] - The company's total assets increased from RMB 22,366,000,000.00 at the end of 2021 to RMB 24,900,000,000.00 at the end of 2022, reflecting a growth of approximately 11.3%[114] - Cash and cash equivalents rose to RMB 10,411,348,410.09, accounting for 41.87% of total assets, up from 40.88% in the previous year[114] Investment and Financial Management - The company has capital commitments of approximately RMB 406.79 million as of December 31, 2022, down from RMB 886.35 million at the end of 2021[142] - The investment amount for the year was RMB 40,000,152.05, representing a significant decrease of 95.49% compared to RMB 886,650,000.00 in the previous year[154] - The company received government subsidies totaling RMB 13,843.17 million for the Sichuan Guangda relocation and expansion project[151] - The financial performance indicates a need for improved management of investment risks, as evidenced by the reported losses[158] Risk Management - The report includes an analysis of potential risks and response strategies for future development[19] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[19] - The company emphasizes the importance of not relying on or using such information improperly, as it may lead to investment risks[19]

特此公告。 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-032 丽珠医药集团股份有限公司 关于召开2022年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）于 2023 年 3 月 31 日在指 定信息披露网站巨潮资讯网（www.cninfo.com.cn）披露了公司《2022 年年度报 告》及摘要。 为了加强与公司投资者，特别是中小投资者的沟通和交流，进一步了解公司 2022 年度经营业绩及未来发展情况，公司定于 2023 年 5 月 8 日（星期一）15:00 至 17:00 在全景网举办公司 2022 年度业绩说明会，本次业绩说明会将采用网络 远程的方式举行，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net） 参与本次业绩说明会。 出席本次会议的人员有：公司执行董事兼总裁唐阳刚先生、公司副总裁兼董 事会秘书杨亮先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题， ...

Financial Performance - The company's revenue for Q1 2023 was RMB 3,413,055,191.98, a decrease of 1.90% compared to RMB 3,479,027,465.92 in the same period last year[4] - Net profit attributable to shareholders was RMB 581,909,331.89, representing an increase of 5.17% from RMB 553,293,797.77 year-on-year[4] - Basic and diluted earnings per share increased by 5.08% to RMB 0.62, compared to RMB 0.59 in the same period last year[4] - The company reported a total comprehensive income of RMB 547.85 million, down 8.2% from RMB 596.68 million in the previous year[17] - The gross profit margin for the quarter was approximately 63.1%, compared to 66.1% in the same quarter last year[17] - The company’s financial expenses showed a significant improvement, with a net financial income of RMB 8.75 million compared to a loss of RMB 37.93 million in Q1 2022[17] Cash Flow - The net cash flow from operating activities decreased by 57.80% to RMB 299,784,593.85, down from RMB 710,308,938.96 in the previous year[4] - The net cash flow from operating activities was RMB 299.78 million, a significant decrease of 57.8% compared to RMB 710.31 million in Q1 2022[18] - Cash inflows from financing activities decreased by 36.98% to RMB 1,070,315,870.74, mainly due to a reduction in borrowings compared to the previous period[9] - Cash outflows from financing activities decreased by 43.97% to RMB 753,630,238.36, primarily due to lower loan repayments[9] - The net increase in cash and cash equivalents decreased by 36.83% to RMB 527,826,015.13, mainly due to increased raw material procurement costs affecting daily operational cash flow[9] Assets and Liabilities - Total assets at the end of the reporting period were RMB 25,620,821,364.99, an increase of 3.04% from RMB 24,864,825,366.23 at the end of the previous year[4] - Total current assets increased to RMB 17,868,009,401.34 from RMB 16,987,297,040.38, representing a growth of approximately 5.17%[15] - Total liabilities increased to RMB 10,204,667,286.46 from RMB 9,928,573,774.51, marking an increase of about 2.78%[16] - Short-term borrowings rose to RMB 1,800,000,000.00 from RMB 1,622,239,859.89, an increase of approximately 11.00%[16] - Long-term borrowings increased to RMB 2,225,976,993.70 from RMB 1,974,444,042.88, representing a growth of about 12.74%[16] Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 56,429, with the largest shareholder holding 33.09% of the shares[10] - The company repurchased a total of 5,232,048 A shares, accounting for 0.56% of the total share capital, with a total expenditure of RMB 177,765,444.64[13] - The highest and lowest prices for the repurchased shares were RMB 35.50 and RMB 32.25 per share, respectively[13] Research and Development - Research and development expenses amounted to RMB 311.41 million, up 8.0% from RMB 288.33 million in Q1 2022[17] - The company reported a significant decrease in development expenses by 53.43% to RMB 125,253,323.41, primarily due to the approval of a new product[7] Government Subsidies - The company reported a total of RMB 40,295,342.15 in government subsidies recognized in the current period[5] Inventory and Cash Equivalents - Cash and cash equivalents rose to RMB 10,868,918,125.10, up from RMB 10,411,348,410.09, an increase of about 4.39%[15] - Inventory increased to RMB 2,238,022,180.23 from RMB 2,045,341,552.12, reflecting a growth of approximately 9.4%[15] - The company's cash and cash equivalents accounted for approximately 60.8% of total current assets[15] Financial Liabilities - The company experienced a 478.94% increase in trading financial liabilities, reaching RMB 4,110,695.40, mainly due to changes in forward foreign exchange contracts[7] Exchange Rate Impact - The impact of exchange rate changes on cash and cash equivalents worsened by 147.55%, resulting in a loss of RMB 23,818,029.01 from foreign currency holdings[9] Audit Information - The company did not conduct an audit for the Q1 2023 report[19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第一季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」或「公司」，連同其附 屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B條以 及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及本公司董事會（「董事會」）全體成員保證信息披露的內容真實、準確、完整，沒有虛假 記載、誤導性陳述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第一季度報告（「本 ...

[0 -> 28] 大家好欢迎参加力珠集团2022年业绩交流会目前所有参会者均处于静音状态现在开始Follow me的声明声明播报完毕后主持人可直接开始发言谢谢本次电话会议仅服务于新业证券客户会议音频及文字记录的内容版权为新业证券所有内容必须经新业证券审核后方可留存 [29 -> 51] 未经允许和授权转载转发此次会议内容均属侵权新义证券将保留追究其法律责任的权利电话会议所有参会人员不得泄露内幕信息以及未公开重要信息涉及外部嘉宾发言的新义证券不保障其发言内容的准确性与完整性 [51 -> 77] 深夜证券不承担外部嘉宾发言内容所引起的任何损失及责任不承担因转载转发引起的任何损失及责任市场有风险投资需谨慎提醒投资者注意投资风险审慎参考会议内容各位投资人上午好欢迎来到力柱集团2022年业绩交流会 [77 -> 105] 我們今天非常榮幸的邀請到公司管理層為我們線上解讀公司2022年的經營情況今天出席的公司領導有公司執行董事、總裁唐陽剛先生副董裁、財務負責人副董裁、董事會秘書楊亮先生研究院院長、化學藥首席科學家與務求公司總經理許堅先生我是興業證券的醫藥分析師黃漢陽 [105 -> 134] 那今天和我一同在线主持的 ...

Financial Performance - In 2022, the company achieved a revenue of RMB 12,629.58 million, representing a year-on-year growth of 4.69%[8] - The net profit attributable to shareholders was RMB 1,909.39 million, with a year-on-year increase of 7.53%[8] - The net cash flow from operating activities increased by 45.75% to CNY 2,772,671.30 thousand in 2022, compared to CNY 1,902,328.14 thousand in 2021[38] - The total assets as of December 31, 2022, were CNY 24,864,825.37 thousand, an increase of 11.14% from CNY 22,371,915.59 thousand in 2021[38] - The total liabilities increased by 23.17% to CNY 9,928,573.77 thousand in 2022, compared to CNY 8,060,890.80 thousand in 2021[38] - The basic earnings per share for 2022 was CNY 2.04, a 7.37% increase from CNY 1.90 in 2021[38] - The company's net assets attributable to shareholders increased by 6.71% to CNY 13,876,020.67 thousand in 2022, compared to CNY 13,003,763.63 thousand in 2021[38] - The company reported a decrease in the equity attributable to shareholders as a percentage of total assets to 55.81% in 2022, down from 58.13% in 2021[38] Dividends and Shareholder Returns - The company proposed a cash dividend of RMB 16.00 per 10 shares for the 2022 fiscal year, pending approval at the annual general meeting[8] - The board of directors has proposed a cash dividend of RMB 16.00 per 10 shares (including tax) for the 2022 fiscal year, pending approval at the annual general meeting[21] - The company will not issue bonus shares or conduct capital reserve transfers in the annual dividend plan[21] Research and Development - The company aims to enhance R&D efficiency and maintain its leading advantage in innovative drugs and complex formulations[13] - The company focuses on R&D innovation, particularly in unmet clinical needs, with a pipeline emphasizing innovative drugs and complex formulations[49] - The company has 26 ongoing key projects in R&D, with 5 in the production application stage and 3 in clinical trial approval stage[105] - The company has 86 ongoing research projects, with 1 in clinical stage and 15 technical improvement projects as of the end of 2022[108] - R&D expenses for the year totaled approximately RMB 1,401.27 million, a decrease of 8.01% from RMB 1,523.26 million in 2021, accounting for 11.10% of total revenue[103] Market and Product Development - The company is actively pursuing international collaboration opportunities to strengthen its market position and achieve sustainable development[11] - The company successfully launched the injection of Apalutamide in Indonesia, marking a significant milestone in international business expansion[57] - The company is focusing on innovative drug development in oncology, autoimmune diseases, and reproductive health, with several key projects progressing through clinical trials[62] - The company is advancing the development of a dual-valent vaccine against COVID-19 variants, with promising results in neutralizing efficacy against Omicron variants[60] - The company has completed the submission of registration materials for multiple products in overseas markets, with 19 product specifications approved in 11 countries/regions as of December 31, 2022[59] Corporate Social Responsibility - The company has committed approximately RMB 9.98 million to public welfare donations during the reporting period[12] - The company will continue to actively respond to national policy calls and strengthen social responsibility, focusing on providing precise assistance to chronic and rare disease populations[14] - The company aims to achieve carbon neutrality by 2055, emphasizing sustainable development and increasing investment in environmental protection[14] - The company expresses gratitude to shareholders, employees, and partners for their long-term support[14] Risk Management and Compliance - The company has analyzed potential risk factors and response strategies for future development in the management discussion and analysis section of the report[21] - The report includes forward-looking statements that may be affected by risks and uncertainties, and actual results may differ significantly[21] - The company emphasizes the importance of accurate and complete financial reporting, ensuring no misleading statements or omissions[20] Operational Efficiency - The marketing team enhanced professional and refined management, focusing on evidence-based and collaborative marketing strategies[11] - The company is enhancing its production and quality management systems to improve delivery capabilities and reduce operational costs, while promoting green production initiatives[58] - The company has established a comprehensive quality management system covering production, research, and sales processes, ensuring product safety and stability[78] Strategic Planning - The company anticipates that the Chinese pharmaceutical market will recover in 2023, with significant growth potential in the biopharmaceutical sector[13] - The company is focused on expanding overseas markets and advancing the consistency evaluation of related drugs to enhance competitiveness[195] - The company is prioritizing the development of high-value products and enhancing its market resilience through strategic planning and execution[183] Environmental Initiatives - The company is committed to energy conservation and emission reduction actions to meet its energy-saving and carbon reduction targets[14] - The company adheres to national environmental policies and regulations, increasing investment in environmental protection and aiming for carbon neutrality by 2055[199] Investment and Financing - The company reported a net increase in cash and cash equivalents of RMB 947.33 million, a significant improvement compared to a decrease of RMB 826.74 million in 2021[115] - The company received government subsidies amounting to RMB 183.35 million, contributing to 7.87% of total profit[120] - The total amount of funds raised by the company through a non-public offering was RMB 145,782.00 million, with RMB 142,030.04 million remaining after deducting issuance costs[165]